The first approved oncolytic virus drug, T-VEC, is based on a genetically modified herpes simplex virus type 1 encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and is used to treat unresectable melanoma [130]. This evidence concerns the gene CSF2 and melanoma.